IL218032A0 - Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors - Google Patents

Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors

Info

Publication number: IL218032A0
Authority: IL; Israel
Prior art keywords: imidazopyridine; phosphodiesterase; inhibitors; imidazopyrimidine derivatives; imidazopyrimidine
Prior art date: 2009-09-24

Application number

IL218032A

Other versions

IL218032A (en

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-24

Filing date

2012-02-09

Publication date

2012-04-30

2012-02-09 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2012-04-30 Publication of IL218032A0 publication Critical patent/IL218032A0/en

2014-06-30 Publication of IL218032A publication Critical patent/IL218032A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL218032A 2009-09-24 2012-02-09 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors IL218032A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09171253		2009-09-24
PCT/EP2010/063830 WO2011036127A1 (en)	2009-09-24	2010-09-21	Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors

Publications (2)

Publication Number	Publication Date
IL218032A0 true IL218032A0 (en)	2012-04-30
IL218032A IL218032A (en)	2014-06-30

Family

ID=43416552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL218032A IL218032A (en)	2009-09-24	2012-02-09	Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors

Country Status (22)

Country	Link
US (2)	US8017604B2 (en)
EP (1)	EP2480546B1 (en)
JP (1)	JP5629322B2 (en)
KR (1)	KR101426624B1 (en)
CN (1)	CN102548991B (en)
AR (1)	AR078437A1 (en)
BR (1)	BR112012006531A2 (en)
CA (1)	CA2770087C (en)
CL (1)	CL2012000708A1 (en)
CY (1)	CY1116120T1 (en)
DK (1)	DK2480546T3 (en)
ES (1)	ES2530884T3 (en)
HR (1)	HRP20150345T1 (en)
IL (1)	IL218032A (en)
MX (1)	MX2012003469A (en)
PE (1)	PE20121438A1 (en)
PL (1)	PL2480546T3 (en)
PT (1)	PT2480546E (en)
RU (1)	RU2502737C2 (en)
SI (1)	SI2480546T1 (en)
TW (1)	TWI402268B (en)
WO (1)	WO2011036127A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8470820B2 (en) *	2010-01-22	2013-06-25	Hoffman-La Roche Inc.	Nitrogen-containing heteroaryl derivatives
KR20140048079A (en)	2011-02-01	2014-04-23	교와 핫꼬 기린 가부시키가이샤	Ring-fused heterocyclic derivative
KR20140009372A (en)	2011-02-18	2014-01-22	알러간, 인코포레이티드	Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8975276B2 (en) *	2011-06-29	2015-03-10	Bristol-Myers Squibb Company	Inhibitors of PDE10
EP2574607A1 (en)	2011-09-06	2013-04-03	F. Hoffmann-La Roche AG	PDE10 modulators
SG11201400759RA (en) *	2011-09-19	2014-07-30	Hoffmann La Roche	Triazolopyridine compounds as pde10a inhibitors
WO2014071044A1 (en)	2012-11-01	2014-05-08	Allergan, Inc.	Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2951176A1 (en) *	2013-01-31	2015-12-09	F. Hoffmann-La Roche AG	Radiolabeled compounds
CN105189493B (en) *	2013-02-27	2017-04-12	持田制药株式会社	Novel pyrazole derivative
MX2015014353A (en)	2013-04-29	2016-04-07	Hoffmann La Roche	2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES.
CN105164126B (en) *	2013-04-30	2017-05-31	豪夫迈·罗氏有限公司	The Pd catalytic couplings of pyrazole amide
US10039764B2 (en)	2013-07-12	2018-08-07	University Of South Alabama	Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
MX2016003422A (en)	2013-09-26	2016-06-28	Hoffmann La Roche	Imidazo[1,2-a]pyridin-7-amines as imaging tools.
US9200016B2 (en)	2013-12-05	2015-12-01	Allergan, Inc.	Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
LT3507291T (en)	2016-09-02	2021-09-10	Cyclerion Therapeutics, Inc.	Fused bicyclic sgc stimulators
CN113698406A (en) *	2021-08-30	2021-11-26	成都药明康德新药开发有限公司	Synthesis method of 6-methylpyrazolo [1,5-A ] pyrimidine-3-amine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60018037T2 (en) *	1999-11-10	2006-01-12	Ortho-Mcneil Pharmaceutical, Inc.	SUBSTITUTED 2-ARYL-3- (HETEROARYL) -IMIDAZO [1,2-ALPHA] PYRIMIDINE AND ITS RELATED MEDICAMENT AND METHOD
SE0102808D0 (en) *	2001-08-22	2001-08-22	Astrazeneca Ab	New compounds
CA2492138C (en) *	2002-07-12	2011-01-11	Yamanouchi Pharmaceutical Co., Ltd.	N-phenyl-(2r,5s)dimethylpiperazine derivative
EP1570847B1 (en)	2002-12-03	2012-04-25	Kyorin Pharmaceutical Co., Ltd.	Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
JP2007508241A (en)	2003-07-31	2007-04-05	バイエル・フアーマシユーチカルズ・コーポレーシヨン	Method for treating diabetes and related disorders using PDE10A inhibitors
WO2005108399A1 (en) *	2004-05-10	2005-11-17	Banyu Pharmaceutical Co., Ltd.	Imidazopyridine compound
US7998974B2 (en) *	2005-03-03	2011-08-16	Sirtris Pharmaceuticals, Inc.	Fused heterocyclic compounds and their use as sirtuin modulators
EP1979350A1 (en) *	2006-01-17	2008-10-15	F.Hoffmann-La Roche Ag	Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
MX2008010668A (en) *	2006-02-21	2008-10-01	Amgen Inc	Cinnoline derivatives as phosphodiesterase 10 inhibitors.
DE102007012645A1 (en) *	2007-03-16	2008-09-18	Bayer Healthcare Ag	Substituted imidazo and triazolopyrimidines
FR2926556B1 (en)	2008-01-22	2010-02-19	Sanofi Aventis	N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

2010
- 2010-09-21 PT PT107609687T patent/PT2480546E/en unknown
- 2010-09-21 EP EP10760968.7A patent/EP2480546B1/en not_active Not-in-force
- 2010-09-21 SI SI201030869T patent/SI2480546T1/en unknown
- 2010-09-21 TW TW099132094A patent/TWI402268B/en not_active IP Right Cessation
- 2010-09-21 RU RU2012113128/04A patent/RU2502737C2/en not_active IP Right Cessation
- 2010-09-21 ES ES10760968T patent/ES2530884T3/en active Active
- 2010-09-21 CN CN201080042292.5A patent/CN102548991B/en not_active Expired - Fee Related
- 2010-09-21 BR BR112012006531A patent/BR112012006531A2/en not_active IP Right Cessation
- 2010-09-21 DK DK10760968.7T patent/DK2480546T3/en active
- 2010-09-21 MX MX2012003469A patent/MX2012003469A/en active IP Right Grant
- 2010-09-21 JP JP2012530234A patent/JP5629322B2/en not_active Expired - Fee Related
- 2010-09-21 PL PL10760968T patent/PL2480546T3/en unknown
- 2010-09-21 WO PCT/EP2010/063830 patent/WO2011036127A1/en active Application Filing
- 2010-09-21 US US12/886,657 patent/US8017604B2/en not_active Expired - Fee Related
- 2010-09-21 CA CA2770087A patent/CA2770087C/en not_active Expired - Fee Related
- 2010-09-21 PE PE2012000365A patent/PE20121438A1/en not_active Application Discontinuation
- 2010-09-21 KR KR1020127010422A patent/KR101426624B1/en not_active IP Right Cessation
- 2010-09-23 AR ARP100103465A patent/AR078437A1/en not_active Application Discontinuation
2011
- 2011-06-02 US US13/151,310 patent/US8263584B2/en not_active Expired - Fee Related
2012
- 2012-02-09 IL IL218032A patent/IL218032A/en not_active IP Right Cessation
- 2012-03-22 CL CL2012000708A patent/CL2012000708A1/en unknown
2015
- 2015-03-16 CY CY20151100263T patent/CY1116120T1/en unknown
- 2015-03-27 HR HRP20150345TT patent/HRP20150345T1/en unknown

Also Published As

Publication number	Publication date
KR101426624B1 (en)	2014-08-05
WO2011036127A1 (en)	2011-03-31
EP2480546A1 (en)	2012-08-01
CA2770087C (en)	2014-09-09
TWI402268B (en)	2013-07-21
PE20121438A1 (en)	2012-10-26
CY1116120T1 (en)	2017-02-08
JP2013505911A (en)	2013-02-21
ES2530884T3 (en)	2015-03-06
PT2480546E (en)	2015-02-09
AR078437A1 (en)	2011-11-09
BR112012006531A2 (en)	2016-11-22
US20110294779A1 (en)	2011-12-01
MX2012003469A (en)	2012-04-19
US20110071128A1 (en)	2011-03-24
EP2480546B1 (en)	2014-12-31
TW201116530A (en)	2011-05-16
IL218032A (en)	2014-06-30
CA2770087A1 (en)	2011-03-31
RU2012113128A (en)	2013-11-10
US8263584B2 (en)	2012-09-11
HRP20150345T1 (en)	2015-05-08
CN102548991A (en)	2012-07-04
SI2480546T1 (en)	2015-03-31
CL2012000708A1 (en)	2012-09-07
RU2502737C2 (en)	2013-12-27
US8017604B2 (en)	2011-09-13
CN102548991B (en)	2015-03-25
JP5629322B2 (en)	2014-11-19
PL2480546T3 (en)	2015-05-29
AU2010299927A1 (en)	2012-03-15
KR20120068943A (en)	2012-06-27
DK2480546T3 (en)	2015-02-02

Publication	Publication Date	Title
IL218032A0 (en)	2012-04-30	Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
HK1219950A1 (en)	2017-04-21	Pyrrolopyridines as kinase inhibitors
ZA201203326B (en)	2013-03-27	Imidazopyridine derivatives as jak inhibitors
IL212285A0 (en)	2011-06-30	Azaindole derivatives
IL195010A0 (en)	2009-08-03	Bicyclic derivatives as cetp inhibitors
HK1156026A1 (en)	2012-06-01	Pyrazolopyridine kinase inhibitors
IL215297A0 (en)	2011-12-29	Imidazopyrazines for use as kinase inhibitors
IL216145A0 (en)	2012-01-31	Dihydropyrimidinones for use as bace2 inhibitors
HK1170377A1 (en)	2013-03-01	Substituted xanthine derivatives
IL212842A0 (en)	2011-07-31	Azaindole derivatives as kinase inhibitors
IL210172A0 (en)	2011-03-31	Substituted pyrimidin-4-one derivatives
IL211241A0 (en)	2011-04-28	7-azaindole derivatives
GB201016880D0 (en)	2010-11-17	Phosphodiesterase inhibitors
LT2486039T (en)	2016-10-10	Purine derivatives useful as hsp90 inhibitors
IL224903A (en)	2016-02-29	Imidazo[4,5-c] quinolines as dna-pk inhibitors
HK1177739A1 (en)	2013-08-30	2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-
SI2124944T1 (en)	2012-05-31	Pyrazolo?á3,4-b?åpyridine derivatives as phosphodiesterase inhibitors
ZA201105896B (en)	2012-03-28	[1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
PL3070091T3 (en)	2019-09-30	Benzodioxole derivatives as phosphodiesterase inhibitors
EP2379538A4 (en)	2013-01-02	Heterocyclic compounds as phosphodiesterase inhibitors
EP2473052A4 (en)	2013-03-20	Substituted xanthine derivatives
EP2318401A4 (en)	2013-10-30	Azaindole inhibitors of iap
IL219603A0 (en)	2012-07-31	Imidazopyridine derivatives
GB0918924D0 (en)	2009-12-16	Azaindole derivatives

Legal Events

Date	Code	Title
2014-10-30	FF	Patent granted
2014-12-31	KB	Patent renewed
2016-09-29	KB	Patent renewed
2021-04-29	MM9K	Patent not in force due to non-payment of renewal fees